Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings

Journey Medical Corporation (DERM) reported $15.96 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 21.5%. EPS of -$0.08 for the same period compares to -$0.18 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $15.08 million, representing a surprise of +5.84%. The company delivered an EPS surprise of -14.29%, with the consensus EPS estimate being -$0.07.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Journey Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total net product revenue- Accutane: $3.31 million versus $2.66 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -9.3% change.Total net product revenue- EmrosiTM: $6.25 million compared to the $5.12 million average estimate based on two analysts.Total net product revenue- Qbrexza: $5.03 million compared to the $5.26 million average estimate based on two analysts. The reported number represents a change of -2.6% year over year.View all Key Company Metrics for Journey Medical here>>>Shares of Journey Medical have returned -4.8% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks